1HFS

CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST STROMELYSIN-1 INHIBITED WITH THE N-CARBOXY-ALKYL INHIBITOR L-764,004


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.217 
  • R-Value Work: 0.189 

wwPDB Validation 3D Report Full Report


This is version 1.4 of the entry. See complete history

Literature

Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.

Esser, C.K.Bugianesi, R.L.Caldwell, C.G.Chapman, K.T.Durette, P.L.Girotra, N.N.Kopka, I.E.Lanza, T.J.Levorse, D.A.MacCoss, M.Owens, K.A.Ponpipom, M.M.Simeone, J.P.Harrison, R.K.Niedzwiecki, L.Becker, J.W.Marcy, A.I.Axel, M.G.Christen, A.J.McDonnell, J.Moore, V.L.Olszewski, J.M.Saphos, C.Visco, D.M.Shen, F.Colletti, A.Krieter, P.A.Hagmann, W.K.

(1997) J.Med.Chem. 40: 1026-1040

  • DOI: 10.1021/jm960465t

  • PubMed Abstract: 
  • Carboxyalkyl peptides containing a biphenylylethyl group at the P1' position were found to be potent inhibitors of stromelysin-1 (MMP-3) and gelatinase A (MMP-2), in the range of 10-50 nM, but poor inhibitors of collagenase (MMP-1). Combination of a ...

    Carboxyalkyl peptides containing a biphenylylethyl group at the P1' position were found to be potent inhibitors of stromelysin-1 (MMP-3) and gelatinase A (MMP-2), in the range of 10-50 nM, but poor inhibitors of collagenase (MMP-1). Combination of a biphenylylethyl moiety at P1', a tert-butyl group at P2', and a methyl group at P3' produced orally bioavailable inhibitors as measured by an in vivo model of MMP-3 degradation of radiolabeled transferrin in the mouse pleural cavity. The X-ray structure of a complex of a P1-biphenyl inhibitor and the catalytic domain of MMP-3 is described. Inhibitors that contained halogenated biphenylylethyl residues at P1' proved to be superior in terms of enzyme potency and oral activity with 2(R)-[2-(4'-fluoro-4-biphenylyl)ethyl]-4(S)-n-butyl-1,5-pentane dioic acid 1-(alpha(S)-tert-butylglycine methylamide) amide (L-758,354, 26) having a Ki of 10 nM against MMP-3 and an ED50 of 11 mg/kg po in the mouse pleural cavity assay. This compound was evaluated in acute (MMP-3 and IL-1 beta injection in the rabbit) and chronic (rat adjuvant-induced arthritis and mouse collagen-induced arthritis) models of cartilage destruction but showed activity only in the MMP-3 injection model (ED50 = 6 mg/kg iv).


    Related Citations: 
    • Stromelysin-1: Three-Dimensional Structure of the Inhibited Catalytic Domain and of the C-Truncated Proenzyme
      Becker, J.W.,Marcy, A.I.,Rokosz, L.L.,Axel, M.G.,Burbaum, J.J.,Fitzgerald, P.M.,Cameron, P.M.,Esser, C.K.,Hagmann, W.K.,Hermes, J.D.,Springer, J.P.
      (1995) Protein Sci. 4: 1966
    • Comparison of the Structure of Human Recombinant Short Form Stromelysin by Multidimensional Heteronuclear NMR and X-Ray Crystallography
      Gooley, P.R.,O'Connell, J.F.,Marcy, A.I.,Cuca, G.C.,Axel, M.G.,Caldwell, C.G.,Hagmann, W.K.,Becker, J.W.
      (1996) J.Biomol.NMR 7: 8
    • Inhibition of Matrix Metalloproteinases by N-Carboxyalkyl Peptides
      Chapman, K.T.,Kopka, I.E.,Durette, P.L.,Esser, C.K.,Lanza, T.J.,Izquierdo-Martin, M.,Niedzwiecki, L.,Chang, B.,Harrison, R.K.,Kuo, D.W.,Lin, T.Y.,Stein, R.L.,Hagmann, W.K.
      (1993) J.Med.Chem. 36: 4293
    • Human Fibroblast Stromelysin Catalytic Domain: Expression, Purification, and Characterization of a C-Terminally Truncated Form
      Marcy, A.I.,Eiberger, L.L.,Harrison, R.,Chan, H.K.,Hutchinson, N.I.,Hagmann, W.K.,Cameron, P.M.,Boulton, D.A.,Hermes, J.D.
      (1991) Biochemistry 30: 6476
    • The NMR Structure of the Inhibited Catalytic Domain of Human Stromelysin-1
      Gooley, P.R.,O'Connell, J.F.,Marcy, A.I.,Cuca, G.C.,Salowe, S.P.,Bush, B.L.,Hermes, J.D.,Esser, C.K.,Hagmann, W.K.,Springer, J.P.,Johnson, B.A.
      (1994) Nat.Struct.Mol.Biol. 1: 111


    Organizational Affiliation

    Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
STROMELYSIN-1
A
160Homo sapiensGene Names: MMP3 (STMY1)
EC: 3.4.24.17
Find proteins for P08254 (Homo sapiens)
Go to Gene View: MMP3
Go to UniProtKB:  P08254
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
L04
Query on L04

Download SDF File 
Download CCD File 
A
6-(4'-FLUORO-BIPHENYL-4-YL)-4-(3-METHYL-1-PHENYLCARBAMOYL-BUTYLCARBAMOYL)-2-[4-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-BUTYL]-HEXANOIC ACID
L004
C43 H48 F N3 O5
WSHMSPGZDPZGRV-GZYXPWJKSA-N
 Ligand Interaction
CA
Query on CA

Download SDF File 
Download CCD File 
A
CALCIUM ION
Ca
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
L04Ki: 2 nM (100) BINDINGDB
L04Ki: 2 nM BINDINGMOAD
L04Ki: 2 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.217 
  • R-Value Work: 0.189 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 84.140α = 90.00
b = 85.350β = 90.00
c = 55.260γ = 90.00
Software Package:
Software NamePurpose
X-PLORphasing
X-PLORmodel building
R-AXISdata reduction
X-PLORrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 1997-02-13 
  • Released Date: 1998-02-18 
  • Deposition Author(s): Becker, J.W.

Revision History 

  • Version 1.0: 1998-02-18
    Type: Initial release
  • Version 1.1: 2008-03-24
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2012-02-22
    Type: Database references
  • Version 1.4: 2017-11-29
    Type: Derived calculations, Other